# TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)

> **NCT00387881** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 679 (actual)

## Conditions studied

- Migraine, Without Aura

## Interventions

- **DRUG:** sumatriptan succinate / naproxen sodium
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00387881
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 679 (ACTUAL)
- **Last updated:** 2016-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00387881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00387881, "TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00387881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*